The Prognostic Role of the Cancer Stem Cell Marker CD44 in Ovarian Cancer: a Meta-analysis

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2017 Jan 11

PMID 28070170

Citations 34

Authors

Jiaying Lin

Ding Ding

Affiliations

Soon will be listed here.

Abstract

Background: CD44 has recently been reported as a cancer stem cell marker in ovarian cancer. However, the clinicopathological and prognostic value of this marker in ovarian cancer remains controversial; Here, we aimed to investigate the correlation between CD44 expression and the clinicopathological features or survival of ovarian cancer patients.

Methods: An extensive literature search in the PubMed, EMBASE, and Wanfang databases (up to June 1, 2016) was conducted to identify studies that assessed the clinical or prognostic significance of CD44 expression in ovarian cancer. A meta-analysis was then performed to clarify the association between CD44 expression and clinical outcomes of ovarian cancer patients.

Results: A total of 18 publications consisting of 2161 patients were included for this meta-analysis. Our data reveal that CD44-positive expression in ovarian cancers were significantly associated with a high TMN stage (pooled OR = 2.11, 95% CI 1.26-3.53, P = 0.004) and poor 5-year overall survival (RR = 1.42, 95% CI 1.01-2.00, P = 0.05). However, CD44 expression was not associated with tumor grade, lymphatic metastasis, age of the patients, residual tumor size, response to chemotherapy, or ascites volume (P > 0.05).

Conclusion: Detection of CD44 may be an effective tool for pathological diagnosis and prognostic prediction of ovarian cancer patients in clinical applications.

Citing Articles

Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma.

Feharsal Y, Andrijono A, Singoprawiro C, Lisnawati L, Pakasi T, Putra A Asian Pac J Cancer Prev. 2024; 25(2):513-519.

PMID: 38415537 PMC: 11077116. DOI: 10.31557/APJCP.2024.25.2.513.

The Role of Cancer Stem Cell Markers in Ovarian Cancer.

Fraszczak K, Barczynski B Cancers (Basel). 2024; 16(1).

PMID: 38201468 PMC: 10778113. DOI: 10.3390/cancers16010040.

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges.

Szymanowski W, Szymanowska A, Bielawska A, Lopez-Berestein G, Rodriguez-Aguayo C, Amero P Cancers (Basel). 2023; 15(21).

PMID: 37958473 PMC: 10647731. DOI: 10.3390/cancers15215300.

Spontaneous metastasis xenograft models link CD44 isoform 4 to angiogenesis, hypoxia, EMT and mitochondria-related pathways in colorectal cancer.

Everest-Dass A, Nersisyan S, Maar H, Novosad V, Schroder-Schwarz J, Freytag V Mol Oncol. 2023; 18(1):62-90.

PMID: 37849446 PMC: 10766209. DOI: 10.1002/1878-0261.13535.

Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer.

Breusa S, Zilio S, Catania G, Bakrin N, Kryza D, Lollo G Front Oncol. 2023; 13:1125868.

PMID: 37287910 PMC: 10242058. DOI: 10.3389/fonc.2023.1125868.

References

Zeimet A, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J . Ovarian cancer stem cells. Neoplasma. 2012; 59(6):747-55. DOI: 10.4149/neo_2012_094. View

Afify A, Craig S, Paulino A, Stern R . Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol. 2005; 9(6):312-8. DOI: 10.1016/j.anndiagpath.2005.07.004. View

Idzerda R, Carter W, Nottenburg C, Wayner E, Gallatin W, John T . Isolation and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium. Proc Natl Acad Sci U S A. 1989; 86(12):4659-63. PMC: 287330. DOI: 10.1073/pnas.86.12.4659. View

Zhang J, Chang B, Liu J . CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Hum Pathol. 2013; 44(9):1882-9. PMC: 3752324. DOI: 10.1016/j.humpath.2013.02.016. View

Rodriguez-Rodriguez L, Sancho-Torres I, Mesonero C, Gibbon D, Shih W, Zotalis G . The CD44 receptor is a molecular predictor of survival in ovarian cancer. Med Oncol. 2003; 20(3):255-63. DOI: 10.1385/MO:20:3:255. View

Bourboulia D, Stetler-Stevenson W . Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010; 20(3):161-8. PMC: 2941566. DOI: 10.1016/j.semcancer.2010.05.002. View

Wang H, Tan M, Zhang S, Li X, Gao J, Zhang D . Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol Sci. 2015; 16(2):3391-404. PMC: 4346902. DOI: 10.3390/ijms16023391. View

Dong W, Sun X, Yu B, Luo H, Yu J . Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol. 2003; 9(11):2596-600. PMC: 4656549. DOI: 10.3748/wjg.v9.i11.2596. View

Tjhay F, Motohara T, Tayama S, Narantuya D, Fujimoto K, Guo J . CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer. Cancer Sci. 2015; 106(10):1421-8. PMC: 4638001. DOI: 10.1111/cas.12765. View

10.

Gallatin W, Weissman I, Butcher E . A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature. 1983; 304(5921):30-4. DOI: 10.1038/304030a0. View

11.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

12.

Hong S, Wen J, Bang S, Park S, Song S . CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 2009; 125(10):2323-31. DOI: 10.1002/ijc.24573. View

13.

Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T . High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci. 2012; 20(5):605-15. PMC: 3635069. DOI: 10.1177/1933719112461183. View

14.

Zhu L, Gao J, Hu Z, Schwab C, Zhuang H, Tan M . Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. Am J Cancer Res. 2015; 5(2):830-43. PMC: 4396026. View

15.

Frank N, Schatton T, Frank M . The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010; 120(1):41-50. PMC: 2798700. DOI: 10.1172/JCI41004. View

16.

Cho E, Choi Y, Chae S, Sohn J, Ahn G . Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int. 2006; 56(2):62-70. DOI: 10.1111/j.1440-1827.2006.01925.x. View

17.

Zhang G, Wang Z, Luo W, Jiao H, Wu J, Jiang C . Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma. Gastroenterol Res Pract. 2013; 2013:782581. PMC: 3806359. DOI: 10.1155/2013/782581. View

18.

Wang S, Wong G, de Heer A, Xia W, Bourguignon L . CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope. 2009; 119(8):1518-30. PMC: 2718060. DOI: 10.1002/lary.20506. View

19.

Liang Y, Fang T, Xu H, Zhuo Z . Expression of CD44v6 and Livin in gastric cancer tissue. Chin Med J (Engl). 2012; 125(17):3161-5. View

20.

Chen H, Hao J, Wang L, Li Y . Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer. 2009; 101(3):432-40. PMC: 2720231. DOI: 10.1038/sj.bjc.6605185. View